Cancer research, stimulated

The US federal agency tasked with tackling cancer has laid out a plan to double the number of cancer research projects it funds, prioritizing first-time grants to young researchers and emphasizing genomic approaches to understanding the disease. These goals are attainable, according to linkurl:John Niederhuber,;http://www.cancer.gov/aboutnci/directorscorner/jen director of the National Cancer Institute (NCI), thanks to an infusion of government funding from an increased annual budget and recent

Bob Grant

| 2 min read

These goals are attainable, according to linkurl:John Niederhuber,;http://www.cancer.gov/aboutnci/directorscorner/jen director of the National Cancer Institute (NCI), thanks to an infusion of government funding from an increased annual budget and recently awarded stimulus funds. But since stimulus funds must be spent within two years, Niederhuber said during a speech at the American Association for Cancer Research conference in Denver, the NCI is weighing grant awards carefully. "It falls to NCI to carefully calculate and thoughtfully assume the risks of initially funding some four-year grants with economic stimulus money, knowing that we will need to find additional resources for the out years," Niederhuber said, according to a linkurl:transcript;http://www.cancer.gov/newscenter/pressreleases/AACRspeech2009QandA of his speech. "I believe it falls, as well, to our grantees to come forward with only their strongest science." In 2009 the agency will be able to fund the top 16% of grant applications instead of only the top 12%--last year's payline--based on budgetary increases alone, Niederhuber said. The NCI may be able to fund 25% of applications with the added $1.3 billion that the agency is set to receive as part of the $10 billion in stimulus funding for the National Institutes of Health. But raising the payline is only half the story. "Economic stimulus funds give us the chance to be visionary," Niederhuber said, adding that the NCI will seek to fund more young, first-time investigators, and will emphasize prevention and early diagnosis in the research it supports in the future. "Patients still need better treatments, better prevention, and better early detection," he said. "We must recommit ourselves to answering that call." This recommitment comes in the form of three initiatives--genetic screening of different cancers, developing personalized cancer care drug development platforms, and integrating the work of physical scientists in oncological study--that largely target cancer's molecular roots. Through programs such as the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) and The Cancer Genome Atlas (TCGA), the three year old project on which the NCI collaborates with the National Human Genome Research Institute, researchers hope to identify a slew of genes related to various tumor types, Niederhuber said. TCGA has already identified new genes involved with glioblastoma tumors and has characterized four different subtypes of the deadly cancer. "With that foundation of success, we plan to move TCGA forward, with a goal of identifying all of the relevant genomic alterations in 20 to 25 major tumor types." "We are undoubtedly moving toward the day when cancers will be diagnosed early and controlled," Niederhuber said.
**__Related stories:__***linkurl:Your guide to NIH stimulus funds;http://www.the-scientist.com/blog/display/55588/
[2nd April 2009]*linkurl:How to spend the NIH stimulus;http://www.the-scientist.com/blog/display/55413/
[11th February 2009]*linkurl:Biomedical research is ripe for a stimulus;http://www.the-scientist.com/news/display/55405/
[9th February 2009]

Cancer research, stimulated

The Scientist ARCHIVES

Become a Member of

Meet the Author

Bob Grant

Related Research Resources

Why Do Some People Get Drunk Faster Than Others?

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Sex Differences in Neurological Research

New Frontiers in Vaccine Development

New Approaches for Decoding Cancer at the Single-Cell Level

Organoids as a Tool for Tissue Regeneration Research

Products

Product News

Understanding the Nuts and Bolts of qPCR Assay Controls

Takara Bio USA Holdings, Inc. announces the acquisition of Curio Bioscience, adding spatial biology to its broad portfolio of single-cell omics solutions

Sapio Sciences Announces Enhanced Capabilities for Chemistry, Immunogenicity, GMP and Molecular Biology

Biotium Unveils the Most Sensitive Stains for DNA or RNA with New EMBER™ Ultra Agarose Gel Kits